Non-cytotoxic protein conjugates

Patent metadata

Field	Value
Publication number	US-10619146-B2
Application number	US-201615258282-A
Country	US
Kind code	B2
Filing date	Sep 7, 2016
Priority date	Dec 1, 2004
Publication date	Apr 14, 2020
Grant date	Apr 14, 2020

Abstract

The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, β-endorphin, bradykinin, substance P, dynorphin and/or nociceptin.

First claim

What is claimed is:

1. A non-cytotoxic protein conjugate for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell, the protein comprising:
(i) a targeting moiety that is an agonist of a receptor present on the nociceptive sensory afferent cell, wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell;
(ii) a non-cytotoxic protease or a protease fragment thereof that is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and
(iii) a translocation domain that translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell;
wherein the targeting moiety and the translocation domain are separated by a spacer having an amino acid sequence of 20-29 amino acid residues;
and wherein the conjugate comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 73, 76, 79, 81, 83, 85, 88, 91, 94, 97, and 100.

2. The non-cytotoxic protein conjugate of claim 1 , wherein the targeting moiety and the translocation domain are separated by a spacer having an amino acid sequence of 20-27 amino acid residues.

3. The non-cytotoxic protein conjugate of claim 1 , wherein the translocation domain is a clostridial neurotoxin translocation domain.

4. The non-cytotoxic protein conjugate of claim 3 , wherein the clostridial neurotoxin translocation domain is a botulinum H N domain.

5. The non-cytotoxic protein conjugate of claim 4 , wherein the botulinum H N domain is encoded by SEQ ID NO: 28 or SEQ ID NO: 32.

6. The non-cytotoxic protein conjugate of claim 1 , wherein the nociceptive sensory afferent cell is a primary nociceptive sensory afferent cell.

7. A pharmaceutical composition, comprising the non-cytotoxic protein conjugate of claim 1 and a pharmaceutically acceptable carrier.

8. A method for treating or ameliorating pain in a subject, the method comprising administering to the subject a therapeutically effective amount of the conjugate of claim 1 .

9. A method for treating or ameliorating pain in a subject, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 7 .

10. The method of claim 8 , wherein the pain is chronic pain selected from the group consisting of neuropathic pain, inflammatory pain, headache pain, somatic pain, visceral pain and referred pain.

11. The method of claim 9 , wherein the pain is chronic pain selected from the group consisting of neuropathic pain, inflammatory pain, headache pain, somatic pain, visceral pain and referred pain.

12. The method of claim 1 , wherein the conjugate comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 52, 60, 73, 76, 79, 85, and 91.

Assignees

• Ipsen Bioinnovation Ltd
• Allergan Inc

Inventors

• Foster Keith
• Chaddock John
• Penn Charles
• Aoki Kei Roger
• Francis Joseph
• Steward Lance

Classifications

• C12N9/6432 Primary

  Coagulation factor Xa (3.4.21.6) · CPC title

• A61K38/22

  Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35) · CPC title

• A61K47/67

  Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT · CPC title

• C12Y304/00

  Hydrolases acting on peptide bonds, i.e. peptidases (3.4) · CPC title

• A61K38/48

  acting on peptide bonds (3.4) · CPC title